4-[(苄氧基羰基)氨基]-3-羟基丁酸 | 83349-20-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-[(苄氧基羰基)氨基]-3-羟基丁酸
• 英文名称: 4-<(Benzyloxycarbonyl)amino>-3-hydroxybutanoic acid
• 英文别名: N-Benzyloxycarbonyl-4-amino-3-hydroxybutyric acid；4-(((Benzyloxy)carbonyl)amino)-3-hydroxybutanoic acid；3-hydroxy-4-(phenylmethoxycarbonylamino)butanoic acid
• CAS: 83349-20-6
• 化学式: C₁₂H₁₅NO₅
• 分子量: 253.255
• InChiKey: FHBQZMZFAJJFDA-UHFFFAOYSA-N

物化性质

• 沸点：
  509.7±50.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(苄氧基羰基)氨基]-3-羟基丁酸 在 sodium hydroxide 、 三氟甲磺酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 环己烷 、 乙酸乙酯 为溶剂， 反应 32.0h， 生成 N-Benzyloxycarbonyl-4-amino-3-benzyloxybutyric acid
  参考文献：
  名称：

  Gastaldi, G.; Focher, B.; Guerrini, M., Journal of Carbohydrate Chemistry, 1994, vol. 13, # 7, p. 1009 - 1024

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氨基-3-羟基丁酸 、 氯甲酸苄酯 在 sodium carbonate 作用下， 以 水 为溶剂， 反应 1.5h， 以57%的产率得到4-[(苄氧基羰基)氨基]-3-羟基丁酸
  参考文献：
  名称：

  Absolute configuration of main chain of AAL-toxins.

  摘要：

  AAL-toxins TA(1) 1 and TA(2) 2, host-specific toxins produced by Alternaria alternata, were degraded to 2-methylbutanol, 3-methylnonan-1,9-diol and N-protected 4-aminobutan-1-3-diol, which were further converted to (R)-MTPA esters. These esters were correlated with synthesis samples by comparison of their 500 MHz H-1-NMR spectra. The remaining stereocenters were determined by the comparison of H-1-NMR spectra of 6a and 7 derived from 1 and 2 with those of synthetic model compounds. These data conclude that AAL-toxins possess 2S, 4S, 5R, 11S, 13S, 14R and 15R configurations.

  DOI：

  10.1016/s0040-4020(01)89343-1

文献信息

• Simple Three-Step Synthesis of (<i>R</i>)- and (<i>S</i>)-4-Amino-3-hydroxybutanoic Acid (GABOB) by Stereoselective Aldol Addition
  作者：Manfred Braun、Delia Waldmüller

  DOI：10.1055/s-1989-27410

  日期：——

  A simple synthesis of both (R)- and (S)-GABOB (5) is reported. In the key step, doubly deprotonated (R)- or (S)-2-Hydroxy-1,2,2-triphenylethyl acetate (HYTRA) (1) is added to Cbz-protected glycinal (2).

  报道了一种简单的同时合成(R)-和(S)-GABOB (5)的方法。在关键步骤中，双去质子的(R)-或(S)-2-羟基-1,2,2-三苯基乙基乙酸酯(HYTRA) (1) 被添加到苄氧羰基保护的甘氨酸醛 (2)中。
• A convenient one-pot procedure for synthesis of thiol esters using magnesium ion as a catalyst
  作者：Shunsaku Ohta、Masao Okamoto

  DOI：10.1016/s0040-4039(01)81874-8

  日期：1981.1

  Various thiol esters (R1 COSR2) were prepared in high yields by treatment of 1-acylimidazole with thiols in the presence of a catalytic amount of Mg(OEt)2. Malonic half-thiol esters [R1OCOCH(R3)COSR2] were also prepared in good yields by treating magnesium monoalkyl malonate [R1 OCOCH(R3)COOMg12] with carbonyl-1,1′-diimidazole followed by addition of thiols.

  在催化量的Mg（OEt）2存在下，通过用硫醇处理1-酰基咪唑，可以高收率制备各种硫醇酯（R 1 COSR 2）。还可以通过用羰基-1,1'-二咪唑处理丙二酸单烷基丙二酸镁[R 1 OCOCH（R 3）COOMg12]，然后以高收率制备丙二酸半硫醇酯[R 1 OCOCH（R 3）COSR 2 ] 。硫醇。
• HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：WAGNER Michael

  公开号：US20080167346A1

  公开（公告）日：2008-07-10

  The present invention relates to compounds of the formula I, which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.

  本发明涉及公式I的化合物，其表现出强烈的抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。
• Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
  申请人：Sanofi-Aventis

  公开号：US08088925B2

  公开（公告）日：2012-01-03

  The present invention relates to compounds of the formula I, which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.

  本发明涉及公式I的化合物，其表现出强烈的抗血栓作用，例如适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。
• BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：Furet Pascal

  公开号：US20150126485A1

  公开（公告）日：2015-05-07

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式（I）的化合物：其中Y，Y，R，R2，R3和R4在本发明的摘要中定义；能够抑制Abelson蛋白（ABL1），Abelson相关蛋白（ABL2）和相关嵌合蛋白的酪氨酸激酶酶活性，特别是BCR-ABL1。本发明还提供了制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。